A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Trial Profile

A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Registrational
  • Acronyms Kinect 4
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 08 Jun 2017 Results (n=430) of pooled long-term exposure analysis using patient data from NCT01688037, NCT02274558, NCT02405091 trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2017 Pooled result of long term exposure data from 3 studies (NCT01688037, NCT02274558 and NCT02405091) presented at the 69th Annual Meeting of the American Academy of Neurology
    • 15 Mar 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top